

Bolin Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7252957/publications.pdf>

Version: 2024-02-01

67
papers

4,936
citations

94269

37
h-index

123241

61
g-index

69
all docs

69
docs citations

69
times ranked

7230
citing authors

#	ARTICLE	IF	CITATIONS
1	Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 585-597.	3.2	11
2	Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. <i>Nature Communications</i> , 2021, 12, 2699.	5.8	46
3	Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 303-314.	2.0	11
4	Sensitization of breast cancer to Herceptin by redox active nanoparticles. <i>American Journal of Cancer Research</i> , 2021, 11, 4884-4899.	1.4	0
5	Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. , 2020, 3, 179-198.		11
6	Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. <i>Biological Procedures Online</i> , 2019, 21, 5.	1.4	48
7	Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. <i>Cancer Letters</i> , 2018, 420, 97-108.	3.2	44
8	Epigenetic mechanism of survivin dysregulation in human cancer. <i>Science China Life Sciences</i> , 2018, 61, 808-814.	2.3	26
9	Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. <i>Scientific Reports</i> , 2018, 8, 6829.	1.6	18
10	Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. <i>Cell Cycle</i> , 2018, 17, 985-996.	1.3	15
11	Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells. <i>Biological Procedures Online</i> , 2018, 20, 16.	1.4	12
12	Understanding the biology of HER3 receptor as a therapeutic target in human cancer. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 503-510.	5.7	80
13	Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1389-1400.	1.9	44
14	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. <i>Oncotarget</i> , 2017, 8, 58847-58864.	0.8	12
15	ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells. <i>Anticancer Research</i> , 2017, 37, 6583-6591.	0.5	8
16	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31093.	1.6	102
17	Metformin attenuates transforming growth factor beta (TGF- β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. <i>Cell Cycle</i> , 2016, 15, 1046-1059.	1.3	60
18	The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. <i>Oncotarget</i> , 2016, 7, 2921-2935.	0.8	21

#	ARTICLE	IF	CITATIONS
19	MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 37693-37713.	0.8	28
20	Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. <i>Cancer Letters</i> , 2015, 366, 160-172.	3.2	27
21	MicroRNA regulation and therapeutic targeting of survivin in cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 20-31.	1.4	42
22	Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6143-56.	0.5	9
23	Role of erbB3 receptors in cancer therapeutic resistance. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 190-198.	0.9	37
24	Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models. <i>Cancer Prevention Research</i> , 2014, 7, 199-210.	0.7	73
25	Targeting of erbB3 receptor to overcome resistance in cancer treatment. <i>Molecular Cancer</i> , 2014, 13, 105.	7.9	142
26	Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 116, 652-657.	2.5	107
27	Effect of Photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 244-251.	1.3	13
28	The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. <i>Molecular Cancer</i> , 2013, 12, 134.	7.9	56
29	Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. <i>Cancer Letters</i> , 2013, 335, 343-350.	3.2	23
30	Glucose promotes breast cancer aggression and reduces metformin efficacy. <i>Cell Cycle</i> , 2013, 12, 3759-3769.	1.3	105
31	“Sister” miRNAs in cancers. <i>Cell Cycle</i> , 2013, 12, 3703-3704.	1.3	11
32	Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R101.	2.2	44
33	Abstract B042: Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab. , 2013, , .		0
34	Abstract A070: The erbB3 blocking antibody MM-121 resensitizes trastuzumab-resistant breast cancer cells to trastuzumab-mediated antitumor activity in vitro and in vivo. , 2013, , .		0
35	Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 36-46.	0.0	10
36	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. <i>Cell Cycle</i> , 2012, 11, 367-376.	1.3	178

#	ARTICLE	IF	CITATIONS
37	Transcriptional downregulation of Brca1 and E-cadherin by CtBP1 in breast cancer. <i>Molecular Carcinogenesis</i> , 2012, 51, 500-507.	1.3	43
38	HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. <i>Cancer Letters</i> , 2011, 307, 72-79.	3.2	45
39	Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. <i>BMC Cancer</i> , 2011, 11, 255.	1.1	21
40	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. <i>Cell Cycle</i> , 2011, 10, 2959-2966.	1.3	128
41	Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. <i>Cancer Research</i> , 2011, 71, 4585-4597.	0.4	230
42	Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis. <i>PLoS ONE</i> , 2011, 6, e23270.	1.1	8
43	Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. <i>Carcinogenesis</i> , 2010, 31, 695-702.	1.3	32
44	Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin. <i>Cancer Research</i> , 2010, 70, 1204-1214.	0.4	207
45	HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. <i>Cancer Letters</i> , 2010, 296, 233-240.	3.2	43
46	Metformin induces unique biological and molecular responses in triple negative breast cancer cells. <i>Cell Cycle</i> , 2009, 8, 2031-2040.	1.3	376
47	HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. <i>Cancer Research</i> , 2009, 69, 8403-8411.	0.4	60
48	Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. <i>Cell Cycle</i> , 2009, 8, 909-915.	1.3	467
49	A New Caspase-8 Isoform Caspase-8s Increased Sensitivity to Apoptosis in Jurkat Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-10.	3.0	8
50	Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling. <i>Molecular Cancer Research</i> , 2009, 7, 1882-1892.	1.5	23
51	Preliminary study of cytotoxic effects of photodynamic therapy and immunotherapy on human pancreatic cancer cells. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
52	Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. <i>International Journal of Cancer</i> , 2007, 120, 1874-1882.	2.3	134
53	2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms.. <i>Blood</i> , 2007, 110, 4792-4792.	0.6	0
54	Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1864-1872.	1.9	61

#	ARTICLE	IF	CITATIONS
55	Anticancer Activity of the Antibiotic Cloiquinol. <i>Cancer Research</i> , 2005, 65, 3389-3395.	0.4	209
56	Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. <i>Breast Cancer Research</i> , 2005, 7, R589-97.	2.2	75
57	Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. <i>Breast Cancer Research</i> , 2005, 7, R708-18.	2.2	40
58	Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. <i>Cancer Research</i> , 2005, 65, 879-86.	0.4	82
59	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. <i>Oncogene</i> , 2003, 22, 3205-3212.	2.6	406
60	Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. <i>Cancer Research</i> , 2003, 63, 2425-33.	0.4	54
61	A Novel Single Amino Acid Deletion Caspase-8 Mutant in Cancer Cells That Lost Proapoptotic Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 30159-30164.	1.6	35
62	Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. <i>Prostate</i> , 2001, 47, 21-28.	1.2	32
63	Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. <i>Oncogene</i> , 2001, 20, 1913-1922.	2.6	107
64	The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. <i>Oncogene</i> , 2001, 20, 3726-3734.	2.6	40
65	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	2.6	122
66	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. <i>Molecular Cell</i> , 1998, 2, 581-591.	4.5	335
67	Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1524-1529.	3.0	39